Anito-cel, a BCMA-directed CAR-T candidate, reported responses in all 38 evaluable patients in a phase 1 study of relapsed or refractory multiple myeloma. The dataset also described a favorable safety profile and durable long-term benefit, with trial cohorts representing a sensitive R/R population. While phase 1 results are not confirmatory, “response in all patients” type readouts can reshape development priority when paired with tolerability. The next step for the field is translating durability signals into randomized comparative evidence and confirming manufacturing consistency and safety across broader subgroups.